Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 5,263 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Trevi Therapeutics Price Performance

Shares of NASDAQ:TRVI traded down $0.03 during midday trading on Friday, hitting $6.50. The company had a trading volume of 944,488 shares, compared to its average volume of 1,016,086. Trevi Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $7.39. The stock has a market cap of $628.43 million, a price-to-earnings ratio of -14.77 and a beta of 0.90. The business's 50-day simple moving average is $4.87 and its 200-day simple moving average is $3.88.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. As a group, sell-side analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Summit Investment Advisors Inc. grew its stake in shares of Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after buying an additional 2,894 shares during the period. BNP Paribas Financial Markets grew its position in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after acquiring an additional 6,764 shares during the period. Raymond James Financial Inc. purchased a new position in Trevi Therapeutics in the fourth quarter worth approximately $49,000. Squarepoint Ops LLC acquired a new stake in Trevi Therapeutics during the fourth quarter worth $58,000. Finally, Two Sigma Advisers LP purchased a new stake in Trevi Therapeutics in the fourth quarter valued at $66,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TRVI shares. B. Riley restated a "buy" rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Oppenheimer upped their price target on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reduced their target price on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday, March 19th. Finally, D. Boral Capital restated a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $17.56.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.